New Trends in the 2015 Global Clinical Development Outsourcing Market

Jul 07, 2015, 10:23 ET from Research and Markets

DUBLIN, June 30, 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/z6fr7h/the_new_trends_of) has announced the addition of the "The New Trends of Global Clinical Development Outsourcing Market" report to their offering.

The report, The New Trends of Global Clinical Development Outsourcing Market, provides unique insights into the current development states and the future growth potentials of the global clinical trial service market. The report is designed to reveal the latest development trends of this outsourcing service market in both the developed countries and the emerging countries, including the detailed insights of the new clinical trial outsourcing strategies of major pharma and R&D-focused biotech companies and their current service demands in each of these regions. It also includes the analyses on the new developments of evolving technologies, approaches, and service models for improving clinical trial efficiency. Moreover, the report contains the in-depth analyses of all positive and negative factors that will determine the future growth directions and paces of the clinical trial outsourcing market on both global and regional scale.

The report provides readers a complete picture of the current state of the global clinical trial service market and a clear insight of its future growth potential. It is a must-read book to all pharmaceutical and R&D-focused biotechnology companies that seek clinical trial outsourcing opportunities, clinical trial service providers that need to conceive their future development directions, and venture capital investors that are looking for investment opportunities in the global pharmaceutical outsourcing industry.

Key Findings of the Report


- It has commonly agreed that clinical trials have become increasingly complicated and take more effort to manage. On the other hand, drug companies are still unable to create a fast, accurate and consistent framework for managing all types of data generated during a trial and for ensuring the streamlined flow of information about a trial. The situation thus forces them to seek help from external resources.

- Moreover, the current global environment is also forcing drug companies to come up with better drugs that are developed at lower cost. It in turn forces them to further improve efficiency and increase productivity.

- Challenged by the situation, a new model of virtually integrated drug development has evolved. Today increasing part of drug companies' clinical development work is executed through close partnerships with preferred service providers.

- At present the developed countries still dominate the global clinical trial market. Drug R&D activities in particular clinical trials have increased significantly in the region in the recent years compared with ten years ago. Meanwhile, the clinical trial industry in the region has also experienced numerous changes during the time period.

- Today those major CROs in the developed countries that have sufficiently large facilities, globe-wide capacity, networked investigators, patient database and effective recruiting tools, etc. are increasingly approached by drug companies for close partnership collaboration. It thus results in more consolidations through M&As in the CRO industry.

- On the other hand, because of the increasing complexity of clinical trials, those small to medium-sized CROs that possess niche technical capability are still needed for functional services. Thus, two types of CROs, both major ones and niche service providers, co-exist in the industry at present.

- In parallel to the two CRO sectors, the global clinical trial service market is also split between the developed countries and the emerging markets. Attracted by a number of advantages possessed by the emerging countries, global drug companies increasingly conduct clinical trials in the region.

- Among the emerging countries, Asia has become a prominent location for clinical trials. In early days conducting clinical trials in the region was primarily for cost saving; but today it is primarily attracted by the local pharmaceutical markets. Increasing numbers of global drug companies thus include those key emerging countries in the region into their late phase, multi-site global trials with aims to launch their products in these markets at the same time as in the developed markets.

- As clinical trial cost is still a concern to all drug companies, the CRO model in the low cost regions is considered a right model as long as they are able to deliver the desired quality of service. To a large extent, this determines the future growth directions and potentials of the clinical trial service market in all emerging countries.

- Based on our research, we forecast that the global clinical trial service market will likely reach more than $64 B by 2020, up from $38.4 B at present, representing a CAGR of 9% between 2015 and 2020. By 2020 the average clinical trial outsourcing penetration will likely reach around 72%. In other words, by then close to three fourths of clinical trials will likely be performed by professional CROs.

- In the forecasted global market, the developed countries will likely account for about 66.8% by 2020, down from 76% at present; whereas the emerging countries combined together will likely account for 25.2%, up from 15.7% at present. Of the emerging countries, China is expected to lead the group and experience the fastest growth in the following 5-7 years.

Key Topics Covered:

Executive Summary

  • Latest trends of global clinical development outsourcing
  • Latest trends of clinical development outsourcing in developed countries
  • Latest trends of clinical development outsourcing in emerging countries
  • Outlook of future growth potentials of global clinical development outsourcing market

Chapter One - Latest Trends of Global Clinical Development Outsourcing
1.1. Introduction
1.2. Analysis of low productivity of clinical development
1.3 Low success rates forcing drug companies to make reform on their R&D
1.4 Major pharma companies' new R&D focuses
1.5 Major pharma companies' new R&D models
1.6 Major pharma companies' new R&D outsourcing strategies
1.7 Biotech companies' current R&D outsourcing demands and strategies
1.8 Latest trends of global clinical trial outsourcing

Chapter Two - Latest Trends of Clinical Development Outsourcing in Developed Countries
2.1 Introduction
2.2 Current trends of clinical trials in developed countries
2.3 Major pharma companies' current clinical trial outsourcing demands, strategies and activities
2.4 Current clinical trial outsourcing demands of biotech companies
2.5 Latest trends in clinical trial service market in developed countries

Chapter Three - Latest Trends of Clinical Development Outsourcing in Emerging Countries
3.1 Introduction
3.2 Emerging countries gaining more shares in global clinical trial market
3.3 Latest trends of clinical trials in Asia
3.4 Latest trends of clinical trials in East Europe
3.5 Latest trends of clinical trials in Latin America

Chapter Four - Outlook of Future Growth Potentials of Global Clinical Development Outsourcing Market
4.1 Introduction
4.2 Analysis of future clinical trial outsourcing strategies of major pharma companies
4.3 Analysis of future development trends of global clinical trial industry
4.4 Analysis of future growth patterns of global CRO industry
4.5 Analysis of future growth potentials of global clinical trial outsourcing market
4.6 Analysis of future growth potentials of clinical trial outsourcing market in developed countries
4.7 Analysis of future growth potentials of clinical trial outsourcing market in emerging countries
4.8 Preferred CROs - Major pharma's selection criteria and CRO's development goals

For more information visit http://www.researchandmarkets.com/research/z6fr7h/the_new_trends_of

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com